Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Placebo-Controlled, Randomized, Single-Blind Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease.

Trial Profile

A Phase 2a, Placebo-Controlled, Randomized, Single-Blind Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GCS 100 (Primary)
  • Indications Renal failure
  • Focus Therapeutic Use
  • Sponsors La Jolla Pharmaceutical Company
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 12 Nov 2014 Results were presented at the American Society of Nephrology's (ASN) Kidney Week Annual Meeting according to a La Jolla Pharmaceutical Company media release reporting the results.
    • 12 Nov 2014 Primary endpoint (Change in eGFR from baseline relative to placebo after administration of GCS-100 for 8 weeks in patients with CKD) has been met for 1.5 mg/m2 dose but not for 30 mg/m2 dose according to a La Jolla media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top